Description: This W3ZLCXC monoclonal antibody reacts with human CXCL1. CXCL1, or GRO (growth-related oncogene) alpha, is a pro-inflammatory CXC chemokine first identified by its constitutive overexpression in some tumors. It is closely related to CXCL2 (GRO beta) and CXCL3 (GRO gamma), with which it shares 90% and 86% sequence homology, respectively. These proteins, along with IL-8 or CXCL8, were later found to be critical for neutrophil mobilization and degranulation, as well as vascular permeabilization and angiogenesis. Signaling occurs through the G protein-coupled receptor CXCR2, which is shared with GRO beta and gamma. CXCR2 can also be activated by IL-8, although some studies suggest that the majority of IL-8 activity on neutrophils is mediated by CXCR1.
CXCL1 is secreted by monocytes, epithelial cells, and fibroblasts in response to pro-inflammatory stimuli such as LPS, IL-1 beta, and TNF alpha. Overexpression is observed in many malignant tumors, where it contributes to tumor vascularization and metastasis. Recent data suggests this antibody has slight crossreactivity by ELISA to CXCL2 and CXCL3. This has not been confirmed by flow cytometry. For a more specific antibody to CXCL1, please use clone KTYFLF (cat 50-7515).